(Reuters) – GlaxoSmithKline’s (GSK) COVID-19 vaccine candidate developed with SK bioscience has been submitted for regulatory approval in South Korea after positive positive Phase III clinical data, the British drugmaker said on Friday.
GSK said that SK bioscience will also apply to the World Health Organization (WHO) for emergency use listing and seek authorisations at individual regulatory agencies around the world.
The company said an extended clinical trial is planned to test the vaccine’s effectiveness against the Omicron variant of the virus.
(Reporting by Miyoung Kim; Editing by David Goodman)
